Context Sensitive Modeling of Cancer Drug Sensitivity
暂无分享,去创建一个
Julio Vera | Lyle Ungar | Bo-Juen Chen | Dana Pe’er | D. Pe’er | Lyle Ungar | O. Litvin | J. Vera | Bo-Juen Chen | Oren Litvin
[1] Janos X. Binder,et al. DISEASES: Text mining and data integration of disease–gene associations , 2014, bioRxiv.
[2] Nci Dream Community. A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .
[3] Gajendra P. S. Raghava,et al. Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients , 2014, Scientific Reports.
[4] Laura M. Heiser,et al. A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.
[5] Carlotta Costa,et al. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 , 2013, Proceedings of the National Academy of Sciences.
[6] Tao Xu,et al. Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..
[7] Stacey Price,et al. A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention , 2013, Cancer cell.
[8] Howard L McLeod,et al. Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed , 2013, Science.
[9] R. Radinsky,et al. Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab , 2013, PloS one.
[10] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[11] A. Heck,et al. Next-generation proteomics: towards an integrative view of proteome dynamics , 2012, Nature Reviews Genetics.
[12] S. Novello,et al. Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972) , 2012 .
[13] S. Novello,et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab , 2012, British Journal of Cancer.
[14] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[15] Y. Samuels,et al. Molecular Pathways: Dysregulated Glutamatergic Signaling Pathways in Cancer , 2012, Clinical Cancer Research.
[16] Chris Jones,et al. Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition , 2012, Proceedings of the National Academy of Sciences.
[17] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[18] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[19] R. Ophoff,et al. Unraveling the Regulatory Mechanisms Underlying Tissue-Dependent Genetic Variation of Gene Expression , 2012, PLoS genetics.
[20] Joshua M. Stuart,et al. Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.
[21] M. Spiliotaki,et al. Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. , 2011, Lung cancer.
[22] Y. Ohe,et al. Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer , 2011, Investigational New Drugs.
[23] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[24] R. Tibshirani,et al. Regression shrinkage and selection via the lasso: a retrospective , 2011 .
[25] R. J. Anto,et al. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. , 2011, The international journal of biochemistry & cell biology.
[26] Dean P. Foster,et al. Minimum Description Length Penalization for Group and Multi-Task Sparse Learning , 2011, J. Mach. Learn. Res..
[27] Simon C. Potter,et al. The Architecture of Gene Regulatory Variation across Multiple Human Tissues: The MuTHER Study , 2011, PLoS genetics.
[28] Alkes L. Price,et al. Single-Tissue and Cross-Tissue Heritability of Gene Expression Via Identity-by-Descent in Related or Unrelated Individuals , 2011, PLoS genetics.
[29] H. McLeod,et al. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application , 2011, The Journal of pathology.
[30] Peter A. Jones,et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. , 2010, Cancer research.
[31] A. Thorburn,et al. The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models , 2010, Clinical Cancer Research.
[32] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[33] G. Pagès,et al. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. , 2010, American journal of physiology. Cell physiology.
[34] J. Desai,et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. , 2010 .
[35] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[36] Dana Pe'er,et al. Harnessing gene expression to identify the genetic basis of drug resistance , 2009, Molecular systems biology.
[37] P. Deloukas,et al. Common Regulatory Variation Impacts Gene Expression in a Cell Type–Dependent Manner , 2009, Science.
[38] K. Patterson,et al. Dual-specificity phosphatases: critical regulators with diverse cellular targets. , 2009, The Biochemical journal.
[39] M. Pollak,et al. Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.
[40] Sven Bergmann,et al. A modular approach for integrative analysis of large-scale gene-expression and drug-response data , 2008, Nature Biotechnology.
[41] P. Halban,et al. Increasing GLP-1–Induced β-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator-α and DUSP14 , 2008, Diabetes.
[42] H. Findley,et al. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2 , 2008, Leukemia.
[43] Carine Poussin,et al. Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. , 2008, Diabetes.
[44] Rajat Raina,et al. Constructing informative priors using transfer learning , 2006, ICML.
[45] J. Melo,et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry , 2006, Leukemia.
[46] Marina Konopleva,et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.
[47] H. Zou,et al. Regularization and variable selection via the elastic net , 2005 .
[48] John H. Zhang,et al. Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity , 2005, Neurological research.
[49] Mina J Bissell,et al. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? , 2005, Cancer cell.
[50] J. Testa,et al. Inhibition of Inhibitor of Nuclear Factor-κB Phosphorylation Increases the Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models , 2004, Clinical Cancer Research.
[51] D. Schrump,et al. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. , 2004, The Journal of thoracic and cardiovascular surgery.
[52] Wei-Min Liu,et al. Robust estimators for expression analysis , 2002, Bioinform..
[53] W. Kolch,et al. The role of MAPK pathways in the action of chemotherapeutic drugs. , 2002, Carcinogenesis.
[54] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[55] Y. Yarden,et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53 , 2001, Oncogene.
[56] G. Sledge,et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide , 2000, Oncogene.
[57] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[58] G. Sledge,et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. , 2000, Oncogene.
[59] Jorma Rissanen,et al. Hypothesis Selection and Testing by the MDL Principle , 1999, Comput. J..
[60] R. Salgia,et al. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells , 1998, Leukemia.
[61] D L Morton,et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. , 1997, The American journal of pathology.
[62] R. Tibshirani. Regression Shrinkage and Selection via the Lasso , 1996 .
[63] Thomas M. Cover,et al. Elements of Information Theory , 2005 .
[64] J. Rissanen,et al. Modeling By Shortest Data Description* , 1978, Autom..